Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Influenza Vaccine Effectiveness in European Primary Care Pediatric Practices: 2022-2024.
Lucaccioni H, Maurel M, Pérez-Gimeno G, Buda S, Sève N, Domegan L, de Lange M, Rodrigues AP, Martínez-Baz I, Hagey TS, Mlinarić I, Túri G, Lazar M, García Becerril M, Dürrwald R, Enouf V, O'Leary M, Meijer A, Guiomar R, Trobajo-Sanmartín C, Latorre-Margalef N, Ilić M, Vázquez Rincón IM, Erdwiens A, Falchi A, McKenna A, Hooiveld M, Gómez V, Castilla J, Višekruna Vučina V, Pozo F, Bacci S, Kaczmarek M, Kissling E; European primary care VE group. Lucaccioni H, et al. Among authors: erdwiens a. Pediatrics. 2026 May 1;157(5):e2025072907. doi: 10.1542/peds.2025-072907. Pediatrics. 2026. PMID: 41936398
Identification of the causal odds ratio in test-negative-design studies of COVID-19 vaccine effectiveness.
Delaunay CL, Nunes B, Monge S, de Lange M, Túri G, Machado A, Latorre-Margalef N, Mlinarić I, Lazar M, Botella Rocamora P, Erdwiens A, Sève N, Domegan L, Martínez-Baz I, Hooiveld M, Oroszi B, Guiomar R, Sperk M, Kurečić Filipović S, Pascu C, Linares Dopido JA, Dürrwald R, Rameix-Welti MA, McKenna A, Castilla J, van Hagen C, Knol M, Kaczmarek M, Kissling E. Delaunay CL, et al. Among authors: erdwiens a. Int J Epidemiol. 2026 Feb 18;55(2):dyag039. doi: 10.1093/ije/dyag039. Int J Epidemiol. 2026. PMID: 41921973 Free PMC article. No abstract available.
Vaccine effectiveness against medically attended, laboratory-confirmed influenza in the I-MOVE primary care network in Europe, VEBIS project, 2024/25.
Lucaccioni H, Pozo F, Pérez-Gimeno G, Dürrwald R, Uras M, Domegan L, Oroszi B, Meijer A, Trobajo-Sanmartín C, Ujvari D, Rodrigues AP, Mlinarić I, Lazar M, Rivas Wagner E, Erdwiens A, Enouf V, McKenna A, Túri G, de Lange M, Martínez-Baz I, Latorre-Margalef N, Guiomar R, Kurečić Filipovic S, Dinu S, Mokoroa O, Tolksdorf K, Masse S, Bennett C, Kristóf K, Hooiveld M, Castilla J, Santos J, Višekruna Vučina V, Popescu R, Bacci S, Kaczmarek M, Kissling E. Lucaccioni H, et al. Among authors: erdwiens a. Expert Rev Vaccines. 2026 Dec;25(1):2645378. doi: 10.1080/14760584.2026.2645378. Epub 2026 Mar 17. Expert Rev Vaccines. 2026. PMID: 41816931 Free article.
Influenza vaccine effectiveness from nine studies during drifted A(H3N2) subclade K predominance, Europe, September 2025 to January 2026.
Lucaccioni H, Marques DF, Kirsebom F, Emborg HD, Hamilton M, Whitaker H, Bolt Botnen A, Bucholc M, Pozo F, Andrews N, Trebbien R, Hameed SS, Lauenborg Møller K, O'Doherty MG, Lopez-Bernal J, Morrison K, Cottrell S, Wilton S, Rose AM, Kissling E; European IVE group. Lucaccioni H, et al. Euro Surveill. 2026 Feb;31(7):2600109. doi: 10.2807/1560-7917.ES.2026.31.7.2600109. Euro Surveill. 2026. PMID: 41716088 Free PMC article.
Vaccine effectiveness against influenza A in older adults and the effect of chronic conditions: results from the I-MOVE and VEBIS multicentre European hospital case-control studies, 2015/16-2023/24.
Rose AMC, Nicolay N, Mazagatos C, Martínez-Baz I, Launay O, De Mot L, Bella A, Lazar M, Machado A, Kuliešė M, Abela S, Vučina VV, van Gageldonk-Lafeber R, Bino S, Dürrwald R, Paradowska-Stankiewicz I, Horváth JK, Duffy R, Husa P, McMenamin J, Pozo F, Howard J, Latorre-Millán M, Castilla J, Nguyen LBL, Dauby N, Riccardo F, Ivanciuc A, Gomez V, Jančorienė L, Xuereb G, Petrović G, Marbus S, Vasili A, Tolksdorf K, Bogusz J, Oroszi B, Domegan L, Součková L, Marsh K, Bacci S, Kissling E; I-MOVE & VEBIS Hospital Network teams. Rose AMC, et al. BMC Med. 2025 Nov 3;23(1):602. doi: 10.1186/s12916-025-04426-y. BMC Med. 2025. PMID: 41185010 Free PMC article.
The potential bias introduced into COVID-19 vaccine effectiveness studies at primary care level due to the availability of SARS-CoV-2 tests in the general population.
Lanièce Delaunay C, Nunes B, Monge S, de Lange M, Túri G, Machado A, Latorre-Margalef N, Mlinarić I, Lazar M, Botella Rocamora P, Erdwiens A, Sève N, Domegan L, Martínez-Baz I, Hooiveld M, Oroszi B, Guiomar R, Sperk M, Kurečić Filipović S, Pascu C, Linares Dopido JA, Dürrwald R, Rameix-Welti MA, McKenna A, Castilla J, van Hagen C, Knol M, Bacci S, Kaczmarek M, Kissling E; VEBIS Primary Care Vaccine Effectiveness Group. Lanièce Delaunay C, et al. Among authors: erdwiens a. Int J Epidemiol. 2025 Jun 11;54(4):dyaf086. doi: 10.1093/ije/dyaf086. Int J Epidemiol. 2025. PMID: 40534212 Free PMC article.
Influenza vaccine effectiveness in Europe and the birth cohort effect against influenza A(H1N1)pdm09: VEBIS primary care multicentre study, 2023/24.
Kissling E, Maurel M, Pozo F, Pérez-Gimeno G, Buda S, Sève N, Domegan L, Hooiveld M, Oroszi B, Martínez-Baz I, Guiomar R, Latorre-Margalef N, Mlinarić I, Lazar M, Giménez Duran J, Dürrwald R, Enouf V, McKenna A, de Lange M, Túri G, Trobajo-Sanmartín C, Gomez V, Samuelsson Hagey T, Višekruna Vučina V, Cherciu MC, García Vazquez M, Erdwiens A, Masse S, Bennett C, Meijer A, Kristóf K, Castilla J, Rodrigues AP, Kurečić Filipović S, Ivanciuc AE, Bacci S, Kaczmarek M; European primary care VE group. Kissling E, et al. Among authors: erdwiens a. Euro Surveill. 2025 Jun;30(23):2500011. doi: 10.2807/1560-7917.ES.2025.30.23.2500011. Euro Surveill. 2025. PMID: 40511473 Free PMC article.
COVID-19 Vaccine Effectiveness Against Medically Attended Symptomatic SARS-CoV-2 Infection Among Target Groups in Europe, October 2024-January 2025, VEBIS Primary Care Network.
Laniece Delaunay C, Verdasca N, Monge S, Domegan L, Sève N, Buda S, Meijer A, Lucaccioni H, López Torrijos M, McKenna A, Enouf V, Dürrwald R, In't Velt E, de Valcárcel Laiglesia MÁ, Bennett C, Masse S, Erdwiens A, Hooiveld M, Mlinarić I, Túri G, Rodrigues AP, Martínez-Baz I, Lazar M, Latorre-Margalef N, Borges V, Kaczmarek M, Bacci S, Kissling E; European primary care VE group. Laniece Delaunay C, et al. Among authors: erdwiens a. Influenza Other Respir Viruses. 2025 May;19(5):e70120. doi: 10.1111/irv.70120. Influenza Other Respir Viruses. 2025. PMID: 40395132 Free PMC article.
Interim 2024/25 influenza vaccine effectiveness: eight European studies, September 2024 to January 2025.
Rose AM, Lucaccioni H, Marsh K, Kirsebom F, Whitaker H, Emborg HD, Bolt Botnen A, O'Doherty MG, Pozo F, Hameed SS, Andrews N, Hamilton M, Trebbien R, Lauenborg Møller K, Marques DF, Murphy S, McQueenie R, Lopez-Bernal J, Cottrell S, Bucholc M, Kissling E; European IVE group; Members of the European IVE group. Rose AM, et al. Euro Surveill. 2025 Feb;30(7):2500102. doi: 10.2807/1560-7917.ES.2025.30.7.2500102. Euro Surveill. 2025. PMID: 39980423 Free PMC article.